Protective effects of Helicobacter pylori for IBD are related to the cagA- positive strain

Gut

Volumn 67, Issue 2, 2018, Pages 393-394

  Lord, A R ^a   Simms, L A ^a   Hanigan, K ^a   Sullivan, R ^b   Hobson, P ^c   Radford Smith, G L ^a,d,e  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Abacus ALS   (New Zealand)

^c SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Crohn'S DISEASE; IBD; ULCERATIVE COLITIS

Indexed keywords

CROHN DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 85029175466     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-313805     Document Type: Letter

References (10)

1. Castaño-rodríguez N, Kaakoush NO, Lee WS, et al. Dual role of Helicobacter and Campylobacter species in IBD: A systematic review and meta-analysis. Gut 2017;66:235-49.
2. Pandeya N, Whiteman DC. Prevalence and determinants of Helicobacter pylori sero-positivity in the Australian adult community. J Gastroenterol Hepatol 2011;26:1283-9.
3. Studd C, Cameron G, Beswick L, et al. Never underestimate inflammatory bowel disease: high prevalence rates and confirmation of high incidence rates in Australia. J Gastroenterol Hepatol 2016;31:81-6.
4. Wilson J, Hair C, Knight R, et al. High incidence of inflammatory bowel disease in Australia: A prospective population-based Australian incidence study. Inflamm Bowel Dis 2010;16: 1550-6.
5. Dahlhamer JM, Zammitti EP, Ward BW, et al. Prevalence of inflammatory bowel disease among adults aged >18 years-United States, 2015. MMWR. Morbidity and Mortality Weekly Report 2016;65:1166-9.
6. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23:713-39.
7. Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: A meta-analysis. Cancer Prev Res 2008;1:329-38.
8. Gathungu G, Kim MO, Ferguson JP, et al. Granulocyte-macrophage colony-stimulating factor autoantibodies: A marker of aggressive Crohn's disease. Inflamm Bowel Dis 2013;19: 1671-80.
9. Taylor DN, Blaser MJ. The epidemiology of Helicobacter pylori infection. Epidemiol Rev 1991;13:42-59.
10. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004;4:688-94.